Fairvalue-Calculator Fairvalue-Calculator
EN DE

Noul Co (376930) Fair Value & Analysis

Healthcare · KR · Market cap 34.6B KRW

Price695.00 KRW
Fair Value1,159 KRW
Upside+66.7%
Quality95/100
Evidence: Low Range 869.05 KRW – 1,448 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Noul Co (376930) currently trades at 695.00 KRW, while our model-based Fair Value estimate is 1,159 KRW — implying the stock looks roughly 66.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Noul Co.,Ltd. engages in the in-vitro diagnosis and remote diagnosis business worldwide. It offers miLab, an AI-based blood diagnostic medical device that automates sample preparation, imaging, and analysis. The company also provides malaria diagnostics, blood cell morphology analysis, cancer morphology, immunohistochemistry services, and digital cervical cell analysis solution. Noul Co.,Ltd. was incorporated in 2015 and is headquartered in Yongin-si, South Korea.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -56% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Noul Co (376930) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1,159 KRW versus a price of 695.00 KRW — about +67% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 376930?
Our 21-model fair value for Noul Co is 1,159 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 695.00 KRW.
What is the quality score of 376930?
Noul Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.